NovoCure Ltd (NVCR) stock
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Earnings
NovoCure's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of NovoCure's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026before the open | $193.40M | +15.7% | -$0.09 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 23, 2026before the open | $183.60M | +15.6% | -$0.13 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $174.10M | +12.3% | -$0.62 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $174.40M | +8.1% | -$0.22 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025before the open | $167.20M | +7.8% | -$0.33 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 24, 2025before the open | $158.80M | +5.6% | -$0.36 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 24, 2025before the open | $155.00M | +11.9% | -$0.31 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $161.30M | +20.6% | -$0.61 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024before the open | $155.10M | +21.8% | -$0.28 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 25, 2024before the open | $150.40M | +19.3% | -$0.31 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $138.50M | +13.3% | -$0.36 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024before the open | $133.80M | +4.2% | -$0.45 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 26, 2023before the open | $127.30M | -2.8% | -$0.46 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023before the open | $126.10M | -10.5% | -$0.54 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $122.20M | -11.1% | -$0.50 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | $128.40M | -3.6% | -$0.36 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 27, 2022before the open | $131.00M | -1.9% | -$0.25 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 28, 2022before the open | $140.90M | – | -$0.23 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 28, 2022before the open | $137.50M | – | -$0.04 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $133.20M | – | -$0.25 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021before the open | $133.60M | – | -$0.13 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
NovoCure's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total net revenue | FY2026 | $736.00M – $743.00M | – | New | Oct 29, 2026 |
| Total net revenue | FY2026 | $710.00M – $725.00M | $690.00M – $710.00M | Raised | Jul 23, 2026 |
| Total net revenuesGAAP | FY2026 | $675.00M – $705.00M | – | New | Feb 26, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $24.00M – $34.00M | -$20.00M – $0 | Raised | Oct 29, 2026 |
| Adjusted EBITDA*non-GAAP | FY2026 | $0 – $15.00M | -$15.00M – $0 | Raised | Jul 23, 2026 |
Guidance history
Every forecast NovoCure put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Adjusted EBITDA | FY2026 | $24.00M – $34.00M | Raised |
| Oct 29, 2026 | Total net revenue | FY2026 | $736.00M – $743.00M | New |
| Jul 23, 2026 | Adjusted EBITDA* | FY2026 | $0 – $15.00M | Raised |
| Jul 23, 2026 | Total net revenue | FY2026 | $710.00M – $725.00M | Raised |
| Apr 30, 2026 | Adjusted EBITDA | FY2026 | -$15.00M – $0 | New |
| Apr 30, 2026 | Total net revenue | FY2026 | $690.00M – $710.00M | New |
| Feb 26, 2026 | Adjusted EBITDA* | FY2026 | -$20.00M – $0 | New |
| Feb 26, 2026 | Total net revenues | FY2026 | $675.00M – $705.00M | New |
| Apr 28, 2022 | active patient growth | FY2022 | +2% – +5% | Reaffirmed |
| Feb 24, 2022 | active patient growth | FY2022 | +2% – +5% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases NovoCure filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Update
- Update
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Update
- Results
See a number that looks wrong?